Everjoy Fortune

Everjoy Fortune is a clinical-stage biopharmaceutical company and investment firm focused on developing innovative small-molecule therapies for autoimmune and inflammatory diseases. Headquartered in Beijing, China, the company's research and development division, Everjoy Fortune (Beijing) Pharmaceutical Technology, is advancing a pipeline of selective kinase inhibitors designed to offer enhanced safety and efficacy. Its lead candidate, EF-009, is a selective Tyrosine Kinase 2 (TYK2) inhibitor currently in Phase 2 clinical trials for the treatment of moderate-to-severe plaque psoriasis and atopic dermatitis. In addition to its internal R&D efforts, Everjoy Fortune operates a global investment arm that provides strategic capital to innovative biotechnology companies specializing in areas like mRNA therapeutics and immuno-oncology. The company leverages its expertise in drug discovery and strategic investment to address significant unmet medical needs in the global healthcare market.